Cure8 research brief
The review suggests LJF contains compounds that may reduce intestinal inflammation, support gut barrier health, and influence microbiota—areas directly relevant to ulcerative colitis and colorectal cancer risk. However, clinical evidence is lacking.
Adults with interest in dietary or complementary approaches to gut health, clinicians advising patients on herbal supplements, and researchers studying natural products, microbiome, or immune pathways in IBD and colorectal cancer.
The paper is a narrative review summarizing preclinical and mechanistic evidence rather than reporting new clinical trial results.
It highlights phenolic acids and flavonoids in LJF and their modulation of signaling pathways such as NF-κB and MAPK, effects on oxidative stress, intestinal barrier integrity, and gut microbiota, plus laboratory evidence of anti-tumor actions.
The authors note important limitations: chemical complexity of preparations, limited mechanistic clarity, and a lack of robust clinical evidence supporting use in humans. They call for multiomics studies, improved formulation/delivery approaches, and well-designed clinical trials before LJF can be recommended for intestinal health or cancer prevention.
The review may be useful for patients curious about herbal/dietary approaches and for researchers planning translational studies, but it does not provide clinical guidance or proven therapies.
This is a review (abstract-level content provided) summarizing preclinical and mechanistic studies; it does not present new clinical trial data. Safety, effective dosing, and clinical efficacy of LJF in humans remain unproven.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The review proposes a low-cost, non-immunosuppressive adjunctive strategy targeting the gut microbiome and luminal metabolism to help maintain remission in UC, an area of strong patient interest but limited clinical...
The findings suggest a processed herbal/tea preparation may alter gut metabolites and microbes to reduce colitis in mice, which could guide future dietary or translational research relevant to people with ulcerative...
Early-stage research suggests a specific probiotic strain may reduce inflammation and alter the gut microbiome and immune-related proteins in an animal model of ulcerative colitis, which could point to future therapeutic...
